Skip to contentH
Haemonetics Corp
H
HAEHaemonetics Corp Q3 2026 · 10-Q
Revenue$338.97M$338.97M−2.7% vs Q3 2025 Net Income$44.74M$44.74M+19.3% vs Q3 2025 EPS Diluted$0.95$0.95+28.4% vs Q3 2025 Gross Profit$202,386,000+4.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Haemonetics Corp · CIK 313143 · Engraved from SEC EDGAR
Operating Cash Flowderived$93,564,000+113.8% Free Cash Flowderived$87,215,000+147.6% Margins · derivedGross margin59.7%+4.2 pt vs Q3 2025
Operating margin19.9%+2.9 pt vs Q3 2025
Net margin13.2%+2.4 pt vs Q3 2025
ended Dec 27, 2025 · filed Feb 5, 2026 · 40 d after period end